Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

被引：5

作者：

Custodio, Ana ^{[1
]}

Calles, Antonio ^{[1
]}

Perez-Segura, Pedro ^{[1
]}

机构：

[1] Hosp Univ Clin San Carlos, Dept Med Oncol, ES-28040 Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2010年 / 12卷 / 04期

关键词：

Glioblastoma multiforme; Recurrent disease; Epidermal growth factor receptor; PTEN; Tyrosine kinase inhibitors; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; PHASE-II TRIAL; TUMOR-CELLS; KINASE INHIBITORS; TYROSINE KINASES; THERAPY; TEMOZOLOMIDE; RESISTANCE; ACTIVATION;

D O I：

10.1007/s12094-010-0510-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.

引用

页码：310 / 314

页数：5

共 39 条

[1]

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance [J].

Aldape, KD ;

Ballman, K ;

Furth, A ;

Buckner, JC ;

Giannini, C ;

Burger, PC ;

Scheithauer, BW ;

Jenkins, RB ;

James, CD .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (07) :700-707

[2]

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

[3]

Chakravarti A, 2002, CANCER RES, V62, P200

[4]

Choe G, 2003, CANCER RES, V63, P2742

[5]

Targeting epidermal growth factor receptor - are we missing the mark? [J].

Dancey, JE ;

Freidlin, B .

LANCET, 2003, 362 (9377) :62-64

[6]

Ermoian RP, 2002, CLIN CANCER RES, V8, P1100

[7]

Regulation of the PTEN phosphatase [J].

Gericke, Arne ;

Munson, Mary ;

Ross, Alonzo H. .

GENE, 2006, 374 :1-9

[8]

Goudar RK, 2005, MOL CANCER THER, V4, P101

[9]

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients [J].

Heimberger, AB ;

Hlatky, R ;

Suki, D ;

Yang, D ;

Weinberg, J ;

Gilbert, M ;

Sawaya, R ;

Aldape, K .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1462-1466

[10]

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma [J].

Huang, Paul H. ;

Mukasa, Akitake ;

Bonavia, Rudy ;

Flynn, Ryan A. ;

Brewer, Zachary E. ;

Cavenee, Webster K. ;

Furnari, Frank B. ;

White, Forest M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) :12867-12872

← 1 2 3 4 →